⏱ 1 min read
Background
Founded in Geneva in 2005, Spineart produces implants and prostheses for spinal surgery. The company is based in Plan-les-Ouates.
The key points
Spineart has obtained approval from the US Food and Drug Administration for its Baguera C cervical disc. The approval covers one and two contiguous levels of the cervical spine.
According to GGBa, the device offers an alternative to spinal fusion for selected patients. It preserves motion at the treated level rather than immobilising it. The US market has relatively few cervical disc replacement options.
Key figures
- Nearly 600 patients enrolled in two randomised controlled trials in the United States.
- 85% of implants retain their mobility after ten years, according to a study published in 2023.
- More than 80,000 devices sold worldwide since launch.
- 385 employees, including 135 in Geneva and 95 in Reignier.
What it means for businesses
The approval strengthens Spineart's presence on the US market. The company has also expanded its industrial capacity with a new site in Reignier, Haute-Savoie. It has operations in the United States, Spain, Italy and Germany.
Who says what
Backed by its investors Gimv and EGSB, Spineart intends to accelerate its development, according to Bilan. It aims to become a global benchmark for innovation in spinal surgery.
What's next
The Baguera C joins the company's US offering. This covers motion preservation, posterior fixation, interbody fusion and biologics.
Further reading
Sources
- Bilan – Spineart: Geneva medtech gets the FDA green light
- GGBa – Spineart obtains FDA approval for its BAGUERA C cervical disc
Let’s share Romandy’s news
We build the news together.
An idea, an opinion, a wish, a detail to add? Tell us!

